ABSTRACT
Resumen Objetivo: actualmente, en Colombia están en uso diferentes escalas para estimar el riesgo de morbimortalidad en pacientes con pancreatitis, lo que genera incertidumbre a la hora de clasificar y manejar a estos pacientes. El objetivo de este estudio es analizar la concordancia entre las más usadas en una población atendida a 2670 metros sobre el nivel del mar (msnm). Materiales y métodos: se evaluaron 200 pacientes, entre 18 y 65 años, con diagnóstico de pancreatitis aguda y manejados en el Hospital Universitario San Ignacio de Bogotá (Colombia). Se estimaron tres escalas de riesgo y se clasificaron como pancreatitis con predicción de gravedad si los puntajes de APACHE II eran ≥8, Marshall modificada ≥2, o si tenían 3 o más criterios de Ranson positivos. Se determinó la concordancia entre los resultados usando el estadístico kappa. Resultados: según Marshall, el 45,5 % de los pacientes correspondieron a pancreatitis con predicción de gravedad, mientras que de acuerdo con APACHE II y Ranson se encontró este diagnóstico en un 39,5 % y un 38,5 %, respectivamente. El coeficiente kappa mostró una concordancia débil entre APACHE II y Ranson (kappa: 0,201; intervalo de confianza [IC], 95 %: 0,05-0,34), así como una concordancia pobre entre Ranson y Marshall (kappa: 0,18; IC, 95 %: 0,04-0,32). La concordancia entre APACHE y Marshall fue moderada (kappa: 0,42; IC, 95 %: 0,28-0,56). Conclusiones: existe un pobre acuerdo entre las diferentes escalas de clasificación de riesgo de pancreatitis usadas en Colombia, por lo que no pueden interpretarse como clínicamente equivalentes. Los datos de este estudio demuestran la necesidad de validar las distintas escalas en Colombia y en Latinoamérica. Además, sugieren que la escala de Marshall sobreestima el riesgo en ciudades por encima de los 2000 msnm.
Abstract Introduction: Different scales to estimate the risk of morbidity and mortality in patients with pancreatitis are currently in use in Colombia, which leads to uncertainty when classifying and treating these patients. Objective: This study seeks to analyze agreement between the most used scales to estimate the risk of patient morbidity and mortality in a population treated at 2,670 meters above sea level (m.a.s.l.). Materials and methods: Two hundred patients between 18 and 65 years old, diagnosed with acute pancreatitis, were evaluated and treated at the Hospital Universitario San Ignacio, Bogotá (Colombia). Three risk scales were used for the estimations. Scores ≥ 8 in the APACHE II system, ≥ 2 in the Modified Marshall Score, or 3 or more positive Ranson criteria were classified as pancreatitis with severity prognostic marker. Agreement between the results was determined using the Kappa coefficient. Results: According to the Marshall score, 45.5% of the cases were pancreatitis with predicted severity, while APACHE II and Ranson yielded scores of 39.5% and 38.5%, respectively. The Kappa coefficient showed weak agreement between APACHE II and Ranson (Kappa=0.201; 95%CI 0.05-0.34), poor agreement between Ranson and Marshall (Kappa=0.18; 95%CI 0.04-0.32), and moderate agreement between APACHE II and Marshall (Kappa=0.42; 95%CI 0.28-0.56). Conclusions: There is poor agreement between the pancreatitis severity scoring systems used in Colombia, so they cannot be interpreted as clinically equivalent. The data from this study demonstrate the need to validate the scales in Colombia and Latin America. They also suggest that the Marshall scale overestimates the risk in cities above 2,000 m.a.s.l.
Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Pancreatitis , Indicators of Morbidity and Mortality , Forecasting , Classification , Sea Level , MethodsABSTRACT
BACKGROUND: Etiological treatment of Chagas disease in chronic asymptomatic patients is still in debate and the adverse effects of traditional drugs are one of the main concerns in clinical practice. This study evaluated retrospectively the safety profile of benznidazole (BZN) and identified predictive factors for definite treatment interruption and development of severe reactions in adult patients treated with BZN in Colombia. METHODS: Retrospective follow-up study conducted by review of medical records of adults with chronic Chagas disease treated with BZN in Colombia. A parametric survival analysis based on a generalized gamma distribution was used for assessing risk factors for treatment interruption. A multinomial logistic regression model was used to estimate the probability of severe adverse drug reactions (ADRs). Statistical associations were expressed as time ratios (TR) and adjusted odds ratios (aOR) respectively. RESULTS: In total 224 adults patients treated with BZN were included; 172 (76.8%) completed the standard therapy (60 days of treatment), 205 (91.5%) presented ADRs and 52 cases (23.2%) required treatment interruption. The predominant symptoms were: rash (37.9%), itching (33.7%), epigastric pain (26.4%), abdominal bloating (24.2%) and nausea (22.1%). ADRs were mild (57.4%), moderate (35.5%) and severe (7.3%). Time to treatment interruption was significantly shorter when using doses of BZN ≥ 6 mg/kg/day (TR 0.55; 95% CI 0.39-0.76), presenting severe ADRs (TR 0.12; 95% CI: 0.07-0.19) and eosinophilia (TR 0.68; 95% CI: 0.49-0.94). Female sex (aOR 3.98; 95% CI 1.56-10.16), dose of BZN ≥ 6 mg/kg/day (aOR 1.41; 95% CI 1.17-1.70) and presence of > 3 ADRs (aOR 6.47; 95% CI 1.24-34.34) were considered as risk factors for developing severe ADRs. CONCLUSIONS: Dose, severity of ADRs, eosinophilia and female sex were the main predictors for treatment interruption or severe ADRs. The potential implications of these findings are discussed.
